Coya Therapeutics, Inc. (COYA)
NASDAQ:COYA
Top Page
Coya Therapeutics, Inc.
(NASDAQ:COYA)
Select Model
Select Model
Rating:51Neutral
Price Target:
$4.00
▼(-10.31% Downside)
Action:ReiteratedDate:03/17/26
The score is held back primarily by persistent losses and ongoing cash burn, alongside weak technical trend signals (below major moving averages with negative MACD). Offsetting factors include a debt-free balance sheet with improved equity and positive corporate developments supporting liquidity and clinical progress.
Positive Factors
Debt-free balance sheet
A zero-debt balance sheet materially reduces financial risk and preserves optionality for a clinical-stage biotech. With no scheduled interest or principal service, management can allocate capital to R&D and manufacturing scale-up, extending runway and lowering default/dilution pressure versus highly levered peers.
Negative Factors
Persistent cash burn
Consistent negative operating and free cash flow of roughly $10M+ per year is a structural pressure for a development-stage biotech. Sustained burn necessitates periodic financing, risks dilution, and constrains the pace of parallel development programs unless new non-dilutive funding or revenue emerges.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt-free balance sheet
A zero-debt balance sheet materially reduces financial risk and preserves optionality for a clinical-stage biotech. With no scheduled interest or principal service, management can allocate capital to R&D and manufacturing scale-up, extending runway and lowering default/dilution pressure versus highly levered peers.
Read all positive factors
Coya Therapeutics, Inc. (COYA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$104.38M
Dividend YieldN/A
Average Volume (3M)266.35K
Price to Earnings (P/E)―
Beta (1Y)1.24
Revenue Growth-58.26%
EPS Growth-53.20%
CountryUS
Employees8
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.34
Shares Outstanding23,457,184
10 Day Avg. Volume216,274
30 Day Avg. Volume266,345
Financial Highlights & Ratios
PEG Ratio-0.15
Price to Book (P/B)2.26
Price to Sales (P/S)12.21
P/FCF Ratio-9.04
Enterprise Value/Market Cap0.28
Enterprise Value/Revenue3.64
Enterprise Value/Gross Profit3.66
Enterprise Value/Ebitda-1.43
Forecast
1Y Price Target
$16.25Price Target Upside264.35% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-1.62
Revenue Forecast (FY)$1.92M
Coya Therapeutics, Inc. Business Overview & Revenue Model
Company Description
Coya Therapeutics, Inc., a clinical-stage biotechnology company, develops proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as T...
How the Company Makes Money
COYA is a clinical-stage biotech and does not primarily generate revenue from product sales. Its earnings, when present, are generally expected to come from (1) collaboration and licensing arrangements—such as upfront payments, research and develo...
Coya Therapeutics, Inc. Financial Statement Overview
Summary
Income Statement
26
Negative
Balance Sheet
63
Positive
Cash Flow
32
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 7.95M | 3.55M | 6.00M | 0.00 | 0.00 |
| Gross Profit | 7.92M | -8.31M | 500.68K | -4.41M | 0.00 |
| EBITDA | -20.24M | -17.20M | -7.33M | -9.26M | -4.85M |
| Net Income | -21.23M | -14.88M | -7.99M | -12.24M | -4.89M |
Balance Sheet | |||||
| Total Assets | 49.95M | 44.35M | 41.26M | 8.40M | 4.79M |
| Cash, Cash Equivalents and Short-Term Investments | 46.82M | 38.34M | 32.63M | 5.93M | 4.34M |
| Total Debt | 0.00 | 0.00 | 0.00 | 12.97M | 0.00 |
| Total Liabilities | 6.92M | 4.77M | 5.63M | 16.79M | 1.15M |
| Stockholders Equity | 43.03M | 39.58M | 35.64M | -8.39M | 3.64M |
Cash Flow | |||||
| Free Cash Flow | -10.74M | -10.29M | -11.19M | -7.24M | -4.04M |
| Operating Cash Flow | -10.74M | -10.29M | -11.19M | -7.24M | -3.90M |
| Investing Cash Flow | -1.16M | -25.00K | -543.19K | -525.00K | -136.80K |
| Financing Cash Flow | 20.39M | 16.03M | 38.43M | 9.36M | -340.58K |
Coya Therapeutics, Inc. Technical Analysis
Neutral
4.46
Price Trends
4.55
Negative
5.00
Negative
5.57
Negative
Market Momentum
-0.07
Negative
53.47
Neutral
72.69
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For COYA, the sentiment is Neutral. The current price of 4.46 is above the 20-day moving average (MA) of 4.18, below the 50-day MA of 4.55, and below the 200-day MA of 5.57, indicating a neutral trend. The MACD of -0.07 indicates Negative momentum. The RSI at 53.47 is Neutral, neither overbought nor oversold. The STOCH value of 72.69 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for COYA.
Coya Therapeutics, Inc. Risk Analysis
Coya Therapeutics, Inc. disclosed 80 risk factors in its most recent earnings report. Coya Therapeutics, Inc. reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Coya Therapeutics, Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
53 Neutral | $160.94M | 15.23 | 22.53% | ― | -67.38% | -1076.54% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $104.38M | -4.57 | -62.18% | ― | -58.26% | -53.20% | |
50 Neutral | $484.49M | -7.52 | -65.03% | ― | -84.46% | 33.32% | |
44 Neutral | $47.07M | -2.46 | -159.43% | ― | ― | 62.84% | |
44 Neutral | $163.26M | -1.32 | -30.02% | ― | ― | 25.84% | |
43 Neutral | $89.31M | -9.60 | -353.36% | ― | -10.36% | 42.36% |
* Healthcare Sector Average
COYA
Coya Therapeutics, Inc.
4.46
-0.76
-14.56%
INO
Inovio Pharmaceuticals
1.11
-0.61
-35.47%
SPRO
Spero Therapeutics
2.78
2.04
275.68%
ANVS
Annovis Bio
1.73
0.47
37.30%
NKTX
Nkarta
2.29
0.54
30.86%
STTK
Shattuck Labs
6.78
6.02
792.11%
Coya Therapeutics, Inc. Corporate Events
Business Operations and StrategyPrivate Placements and Financing
Coya Therapeutics Announces Strategic Private Placement Financing
Positive
Jan 30, 2026
On January 29, 2026, Coya Therapeutics, Inc. entered into a securities purchase agreement with Dr. Reddy’s Laboratories and Greenlight Capital for a private placement of 2,522,727 common shares at $4.40 per share, expected to close on or abo...
Business Operations and StrategyFinancial Disclosures
Coya Therapeutics Reports Strong Cash Position and Runway
Positive
Jan 20, 2026
On January 20, 2026, Coya Therapeutics, Inc. informed stockholders that its unaudited cash balance as of December 31, 2025 stood at $46.8 million, providing a projected cash runway into the second half of 2027 and supporting continued operations a...
Business Operations and Strategy
Coya Therapeutics Reports Positive Frontotemporal Dementia Study Data
Positive
Jan 8, 2026
On January 8, 2026, Coya Therapeutics, Inc. reported positive results from an investigator-initiated, open-label proof-of-concept study evaluating a combination of low-dose IL-2 and CTLA4-Ig in nine patients with frontotemporal dementia over six m...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.